Navigation Links
d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
Date:3/25/2013

(PRWEB) March 25, 2013

In July of 2011, the FDA announced that it had approved Xarelto to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery (i). In November, the FDA expanded Xarelto’s approval to include the prevention of stroke in patients with atrial fibrillation. One year later the FDA gave its approval of the drug to prevent the recurrence of blood clots. However, according to The New York Times, an FDA panel voted against approving Xarelto for the treatment of acute coronary syndrome (ACS) (ii). Specifically, the panel was concerned that 15 percent of the participants in a study of Xarelto and ACS dropped out.

According to QuarterWatch, a report published by the Institute for Safe Medication Practices, the FDA received 356 adverse event reports of “serious, disabling, or fatal injury” for Xarelto in the first quarter of 2012 (iii). Additionally, the report stated that blood clots “were the predominant serious adverse events reported, accounting for 158 cases.” By October, the FDA had received 2,754 adverse event reports concerning Xarelto. Among these were 386 cases of pulmonary embolism, 279 cases of deep vein thrombosis, and 107 cases of gastrointestinal hemorrhage (iv).

The Xarelto infographic provides a summary of drug information and lists possible side effects. Additionally, it provides information on a study published in the New England Journal of Medicine, which found that the anticoagulant drug may increase the risk of hemorrhaging (v). Visit the Xarelto section of d’Oliveira & Associates website and view the infographic here.

If you or a loved one has suffered Xarelto side effects, you may want to speak with a lawyer regarding a claim. A personal injury lawyer familiar with new developments in the investigation of Xarelto may be able to assist you in making important personal and legal decisions. Our firm is working with some of the most experienced Xarelto lawyers in the country who are handling these cases.

Please contact the law offices of d'Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) drugs.com/history/xarelto.html
(ii) nytimes.com/2012/05/24/business/fda-panel-votes-against-expansion-of-xarelto.html?_r=4&src=recg&
(iii) ismp.org/quarterwatch/pdfs/2012Q1.pdf
(iv) http://www.adverseevents.com/drugdetail.php?AEDrugID=5158&BrandName=XARELTO
(v) nejm.org/doi/full/10.1056/NEJMoa1111096

Read the full story at http://www.prweb.com/releases/2013/3/prweb10551499.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Help New Bedford Woman Receive $95,000 in Damages for Dog Bite Injury Case #:NB-11736
2. d'Oliveira & Associates Helps Westport, MA Man Receive $100,000 Settlement for Reckless Driving Accident
3. d'Oliveira & Associates Helps Rhode Island Estate Receive the Maximum Compensation Under RI Law of $250,000 Settlement for Fatal Auto Accident
4. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
5. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
6. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
7. d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014
8. d'Oliveira & Associates Helps Fall River, MA Teenager Receive $38,500 in Auto Accident Settlement
9. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
10. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
11. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Mirena IUD Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door ... provide one resource, from start to finish, for Life Safety compliance. These ... Condition surveys requested by the Joint Commission, and fire stopping reviews, inspections, and ...
(Date:5/24/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... & Co., Inc. Headquartered in Albany, New York, Austin & Co., Inc. ... and beyond. As an employee-owned company celebrating over 160 years of service, ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, **Presented by ... , Human error is known to be the major cause of quality and production ... totally eliminated, many human performance problems can be prevented. , How to Write Error ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- ... of its Advisory Board. Joining the Grow Healthy Advisory Board ... of them embody the mission of our organization and bring talent, ... have them as we continue to expand our footprint as the ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of ... each job, ensuring the best suited solution to meet regulatory requirements. Their professional ... their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... Clarifying Vision - Prospects and ... Vision Care What can be expected from ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects. ,Our 190-page ... most lucrative areas in the industry and the future ...
(Date:5/23/2016)... , May 23, 2016 ... reach USD 5.0 billion by 2022, according to a ... generation of medical waste coupled with the lack of ... is expected to drive the demand for reprocessed medical ... devices as compared to that of the original device ...
(Date:5/20/2016)... , May 20, 2016 ... Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation ... Biological Drugs - This New Study Reveals Selling ... Ahead ,What is the future ... the latest technological and commercial analysis. Staying ahead ...
Breaking Medicine Technology: